Literature DB >> 2493352

Phenotypic expression of histocompatibility antigens in human primary tumours and metastases.

F Ruiz-Cabello1, M A Lopez Nevot, J Gutierrez, M R Oliva, C Romero, A Ferron, F Esteban, C Huelin, M A Piris, C Rivas.   

Abstract

HLA class I and II expression was studied on 244 (177 primary and 67 metastatic) solid human tumours of different origin. Alkaline immunophosphatase (APAAP) and immunoperoxidase were used on cryostatic sections to stain MHC antigens. Monomorphic MoAbs were used against class I heavy chain, beta 2-microglobulin, DR, DQ and DP molecules. Class I expression was homogeneous on colon, melanoma and epidermoidal primitive tumours. Loss of HLA class I antigens was more frequent on basal cell carcinomas and sarcomas and was related to tumour differentiation on larynx carcinoma. Class I expression was heterogeneous on breast, larynx and stomach primitive neoplasias. Class I negative tumours were more frequent on metastatic than on primitive melanomas. Divergence of class I between primary tumours and autologous metastases was observed on melanomas, larynx and colorectal carcinomas. Class II expression was heterogeneous on all tumours and in a large number of cases was associated with high intensity of leukocytic infiltrate. HLA-DR expression was higher than HLA-DP and HLA-DQ (DR greater than DP greater than DQ) and was related to tumour progression. Four human tumour cell lines were modulated with recombinant interferon-gamma for HLA class I and II antigens. Different HLA profiles were obtained: increased class I and II expression, increased class II or a low response. Finally, class I genes from 22 tumours were compared with autologous normal cells by Southern blot analysis: 12 tumours were class I positive and 10 negative. No clear differences in RFLP were observed that could be associated with class I rearrangement. The results are discussed in relation to the role that histocompatibility antigens may play in tumour progression and invasiveness.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2493352     DOI: 10.1007/bf01787025

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  Biological effects of gamma-interferon on human tumor cells: quantity and affinity of cell membrane receptors for gamma-IFN in relation to growth inhibition and induction of HLA-DR expression.

Authors:  U Ucer; H Bartsch; P Scheurich; K Pfizenmaier
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

2.  Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer.

Authors:  A K Sood; D Pereira; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

3.  SB-restricted presentation of influenza and herpes simplex virus antigens to human T-lymphocyte clones.

Authors:  D D Eckels; P Lake; J R Lamb; A H Johnson; S Shaw; J N Woody; R J Hartzman
Journal:  Nature       Date:  1983-02-24       Impact factor: 49.962

4.  The detailed distribution of HLA-A, B, C antigens in normal human organs.

Authors:  A S Daar; S V Fuggle; J W Fabre; A Ting; P J Morris
Journal:  Transplantation       Date:  1984-09       Impact factor: 4.939

5.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

6.  Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness.

Authors:  J Gutierrez; M A López-Nevot; T Cabrera; R Oliva; J Esquivias; F Ruiz-Cabello; F Garrido
Journal:  Exp Clin Immunogenet       Date:  1987

7.  Histocompatibility antigens on murine tumors.

Authors:  R S Goodenow; J M Vogel; R L Linsk
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

8.  Recombinant interferon-gamma increases HLA-DR synthesis and expression.

Authors:  T Y Basham; T C Merigan
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

Review 9.  Expression and susceptibility to modulation by interferons of HLA class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance.

Authors:  D J Ruiter; E B Bröcker; S Ferrone
Journal:  J Immunogenet       Date:  1986 Apr-Jun

10.  Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens.

Authors:  S Carrel; A Schmidt-Kessen; L Giuffrè
Journal:  Eur J Immunol       Date:  1985-02       Impact factor: 5.532

View more
  10 in total

1.  Down-regulation of HLA-A mRNA in peripheral blood mononuclear cell of colorectal cancer.

Authors:  Ming-Chen Zhu; Yi-Jun Xu; Xiong Zou; Feng Yan
Journal:  Int J Colorectal Dis       Date:  2011-09-23       Impact factor: 2.571

2.  Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Authors:  Masanao Saio; Matt Teicher; Gaynor Campbell; Helen Feiner; Yara Delgado; Alan B Frey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx.

Authors:  F Esteban; F Ruiz-Cabello; A Concha; M Pérez-Ayala; J A Sánchez-Rozas; F Garrido
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

4.  Rapidly progressive sacroiliitis in a patient with lymphocytic lymphoma.

Authors:  M R Cohen; G E Carrera; J Lundberg
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

5.  Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.

Authors:  A Maiorana; A M Cesinaro; R A Fano; G Collina
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

6.  p53 and HLA class-I expression are not down-regulated in colorectal cancer liver metastases.

Authors:  Anand G Menon; Rob A E M Tollenaar; Cornelis J H van de Velde; Hein Putter; Connie M Janssen-van Rhijn; Rob Keijzer; Gert Jan Fleuren; Peter J K Kuppen
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 7.  Novel immunotherapies in lymphoid malignancies.

Authors:  Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2015-11-03       Impact factor: 66.675

8.  Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma.

Authors:  J R Goepel; R C Rees; K Rogers; C J Stoddard; W E Thomas; L Shepherd
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

9.  Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx.

Authors:  F Esteban; A Concha; M Delgado; M Pérez-Ayala; F Ruiz-Cabello; F Garrido
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

10.  MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up.

Authors:  F Esteban; M Redondo; M Delgado; F Garrido; F Ruiz-Cabello
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.